OR WAIT null SECS
Symbiosis Pharmaceutical Services is now offering a new bulk lyophilization (freeze drying) service in response to increasing demand in the manufacture of bulk intermediates and APIs by lyophilization.
Sterile manufacturing CMO, Symbiosis Pharmaceutical Services, announced that it is now offering a new bulk lyophilization (freeze drying) service in response to increasing demand in the manufacture of bulk intermediates and APIs by lyophilization. The Scotland-based company has clients in the US, Europe, and Asia.
The company has been providing lyophilization for the sterile filling of vials since its inception, but it has now expanded this offering to provide both aseptic and low bioburden clean room dispensing of bulk materials.
“This service launch has very much been driven by market demand from biotech and pharmaceutical companies requiring either a one-off batch or the ongoing bulk lyophilization of API or finished product,” commented Colin MacKay, CEO of Symbiosis Pharmaceutical Services, said in a press statement.
The company’s biologic and small molecule sterile production capabilities help support biotech and speciality pharmaceutical companies across the world that require products for clinical trials and low volume commercial supply.
After taking delivery of API into Symbiosis’ GMP cleanroom suites, the CMO is able to lyophilize product in appropriate freeze drying trays. As part of the new service, it will also support clients with the development of an optimized cycle as well as supporting with analytical and microbial testing, labelling, controlled temperature storage, and distribution.